SCHEMBL23460893

SCHEMBL23460893

CC1([C@H](NC(=O)c2ccc3ccc(C(F)(F)F)cc3c2OCc2ccc(C(F)(F)F)cc2)C(=O)O)CCCC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CXCR2 P25025 1/20 0.49
▸ KIFC1 Q9BW19 1/20 0.38
▸ MME P08473 2/20 0.38
▸ ACE P12821 2/20 0.38
▸ CPA1 P15085 2/20 0.38
▸ ACE2 Q9BYF1 2/20 0.38
▸ PPARG P37231 3/20 0.36
▸ FFAR1 O14842 2/20 0.36
▸ MRGPRX4 Q96LA9 2/20 0.35
▸ PPARD Q03181 2/20 0.35
▸ PPARA Q07869 2/20 0.35
▸ MAOB P27338 3/20 0.35
▸ PTPN2 P17706 1/20 0.35
▸ PTPN1 P18031 1/20 0.35
▸ PTPN6 P29350 1/20 0.35
▸ PSMB11 A5LHX3 1/20 0.35
▸ PSMA7 O14818 1/20 0.35
▸ PSMB1 P20618 1/20 0.35
▸ PSMA1 P25786 1/20 0.35
▸ PSMA2 P25787 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23460895 1.00 CXCR2 (0.49) CXCR2KIFC1MMEACECPA1
SCHEMBL23461506 0.98 CXCR2 (0.49) CXCR2KIFC1MMEACECPA1
SCHEMBL23461509 0.98 CXCR2 (0.49) CXCR2KIFC1MMEACECPA1
SCHEMBL23460707 0.97 CXCR2 (0.50) CXCR2KIFC1MMEACECPA1
SCHEMBL23460705 0.97 CXCR2 (0.50) CXCR2KIFC1MMEACECPA1
SCHEMBL25548747 0.94 CXCR2 (0.47) CXCR2KIFC1MMEACECPA1
SCHEMBL23461283 0.93 CXCR2 (0.47) CXCR2KIFC1MMEACECPA1
SCHEMBL23461282 0.93 CXCR2 (0.47) CXCR2KIFC1MMEACECPA1
SCHEMBL25548751 0.92 CXCR2 (0.47) CXCR2KIFC1MMEACECPA1
SCHEMBL23461014 0.91 CXCR2 (0.48) CXCR2KIFC1MMEACECPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630498-B2 Arylamides and methods of use thereof GENZYME CORPORATION (US) 2026-05-19 — — US disclosed
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 — — US disclosed
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 — — US disclosed
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 — — US disclosed
WO-2021113806-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION (US) 2021-06-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF CFTR, AADAC, ARSA CXCR2 1205/4885KIFC1 4789/4885MME 1991/4885
US-12630498-B2 Arylamides and methods of use thereof CFTR, CLIC1, CLCN2 CXCR2 63/4885KIFC1 3064/4885MME 2964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback